Kashiv BioSciences has developed several advanced oral drug delivery platforms for controlled, site-specific, pulsatile, timed, delayed, and extended delivery of a wide variety of challenging compounds. We have expertise in improving the oral drug delivery of compounds that exhibit poor solubility, low bioavailability, site-specific absorption, and short half-lives. We have utilized our proprietary drug delivery technologies to build a pipeline of innovative and clinically differentiated 505(b)(2) branded products. We plan to commercialize our technology platforms and internally developed products through licensing, strategic partnering, and profit-sharing joint ventures.
Kashiv has also developed a pipeline of high-quality biosimilars, with two oncology products in advanced stages of development. We are awaiting U.S. FDA approval for filgrastim, and are filing a Biologics License Application (BLA) for pegfilgrastim in 2019. We are interested in in-licensing new biosimilars that have completed analytical similarity testing with innovator-branded biologics for global development and approval. We are also interested in finding commercialization partners for ex-U.S. markets for our internally developed biosimilars.
Kashiv is seeking strategic partnerships for:
- Commercializing our novel 505(b)(2) products
- Out-licensing or co-development opportunities for our drug delivery technologies with partners’ proprietary compounds
- In-licensing of well-characterized biosimilars for U.S. development
- Commercializing our internally developed biosimilars for ex-U.S. markets
For more information on partnering with Kashiv BioSciences, please email email@example.com
Kashiv BioSciences has development collaborations with small to large pharmaceutical companies that has resulted in the development, approval, and commercialization of over 15 complex generics and formulation development of several new chemical entities that leverage our drug delivery, formulation technologies, and pharmaceutical development infrastructure.